K
Keros Therapeutics
Keros Therapeutics, Inc. operates as a biotechnology company
About Keros Therapeutics
Keros Therapeutics is a biopharmaceutical startup that operates in the healthcare sector, specifically in the development of innovative therapies. The company's primary focus is on disorders linked to the dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. In simpler terms, they are working on treatments that can help the body's cells grow and repair themselves more effectively, particularly blood cells and various tissues.
Their business model revolves around leveraging their deep expertise in TGF-ß science to develop and commercialize novel therapeutics. These therapeutics have the potential to modulate TGF-ß signaling, which could provide disease-modifying benefits for patients. This means they are creating new drugs that can potentially change how diseases progress, offering significant benefits to patients.
The company's target market includes patients with disorders linked to the dysfunctional signaling of TGF-ß proteins. This could potentially cover a wide range of patients, given the fundamental role these proteins play in cellular growth and repair.
Keros Therapeutics generates revenue through the development and commercialization of these novel therapeutics. Once a therapy is developed and approved, it can be sold to healthcare providers who administer it to patients. The company's potential for revenue growth lies in the successful development and approval of their therapies, as well as the size of the patient population that could benefit from these treatments.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
News
Open roles
Keros Therapeutics in the Lexington ecosystem
The Keros Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Pontifax Funds- GFGlobal health sciences venture fund
- PFPartners Innovation Fund
Medison Pharma
Series B and later3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Keros Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Keros Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.




